Brazil Atherosclerosis Therapeutics Market Analysis

Brazil Atherosclerosis Therapeutics Market Executive Summary

Brazil Atherosclerosis Therapeutics Market was valued at $70 Mn in 2022 and is estimated to reach $118 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period.

Atherosclerosis is a condition characterized by the buildup of plaque, which is a sticky substance made of cholesterol, fat, calcium, and other materials, inside the walls of arteries. This buildup can lead to the narrowing or obstruction of blood vessels, reducing blood flow and increasing the risk of serious conditions such as heart attacks and strokes. The development of atherosclerosis is influenced by various factors, including high blood pressure, elevated cholesterol levels, diabetes, obesity, smoking, a family history of heart disease, physical inactivity, and an unhealthy diet. Several drugs have demonstrated effectiveness in reducing or preventing the progression of atherosclerosis, including beta-blockers, aspirin, and statins.

In Brazil, the main cause of death, cardiovascular diseases (CVDs), accounts for about one-third of all deaths, while noncommunicable diseases account for 72% of all deaths. Nearly 400,000 deaths are caused by CVDs, with heart failure accounting for 8.9% of these deaths, myocardial infarction accounting for 23.9%, and stroke accounting for 14.1%. For these diseases, the age-standardized mortality rates have consistently decreased by 17.5%, 42.7%, and 42.0%, respectively. With over 222,000 admissions, heart failure is by far the most common reason for hospital stays in Brazil. Age-standardized rates of 475 and 5454 per 100,000 people for the incidence and prevalence of CVD, respectively, show a 26.8% increase in the disease's prevalence.

The Phase 2b clinical trial conducted by DARA Biosciences (DARB3A) to examine the plaque-stabilizing characteristics of its drug candidate, Dara017, for coronary atherosclerosis has been concluded. A Phase 2 clinical trial is presently being conducted by Hyperbranch Polymers Tecnologia (Hybran) to evaluate the safety and effectiveness of HB Therapeutics in individuals suffering from carotid artery stenosis, an indication of atherosclerosis. In July 2023, Biomm (BOMM3) partnered with the University of California, San Diego, to pursue novel treatments for atherosclerosis and other cardiovascular disorders. The ongoing and completed clinical trials, along with collaborative efforts, indicate significant progress in developing innovative therapies for atherosclerosis. This progress fosters optimism for improved treatment options and better outcomes in cardiovascular health.

Market Dynamics

Market Growth Drivers

Increasing Cardiovascular Disease Burden: One of the main causes of CVD, atherosclerosis, is largely responsible for the rising need for alternative forms of treatment. Nearly 400,000 deaths are caused by CVDs in Brazil. Better atherosclerosis treatment methods are required in addition to the growing burden of CVD and the increasing incidence of risk factors such as diabetes, high blood pressure, and unhealthy cholesterol levels.

Aging Population: There is a growing need for atherosclerosis-related therapeutics since the aging of the population greatly increases the susceptibility of the elderly to atherosclerosis. Brazil's aging population is expanding quickly. By 2030, this age group is projected to reach around 50 Mn, making up almost 24% of the population. Since atherosclerosis is more common in the elderly population, there is an increasing need to address the condition's therapeutic needs.

Advancements in Drug Development: The market is expanding because new medications like RNA interference therapy-based cholesterol-lowering drugs like inclisiran and PCSK9 inhibitors provide more and better therapeutic choices. The growing emphasis on atherosclerosis genetic susceptibilities and specific patient profiles taken into consideration for customized treatment regimens creates opportunities for market expansion.

Market Restraints

High Drug Cost: A significant barrier for many people, especially those with lower incomes or less access to healthcare, is the high cost of the medications used to treat atherosclerosis. High prescription medication costs are an issue since they limit market penetration and impede overall growth.

Lack of Awareness: Insufficient knowledge about atherosclerosis and its preventive methods might make it difficult to intervene early and deter people from getting medical attention as soon as possible. People who lack knowledge of atherosclerosis and its prevention strategies may fail to identify the disease's symptoms or act promptly to take preventive action, which could prolong the need for medical intervention and care. The growth of the market is hampered by this lack of knowledge.

Regulatory Hurdles: Prolonged clinical trials and strict regulatory processes can provide obstacles and extra costs for pharmaceutical companies, delaying the arrival of new medications into the market. Businesses may find it challenging to effectively manage the system and plan for approval dates due to the uncertainty created by vague regulations. The regulatory approval process is filled with uncertainty, making it difficult for innovators to forecast needs and review periods. This intricacy necessitates careful planning and coordination at several phases, including clinical trials, manufacturing, and marketing approval, and can result in significant delays in medication development. The market's ability to grow is hampered by regulatory uncertainty.

Healthcare Policies and Regulatory Landscape

The licensing, distribution, and oversight of treatment pharmaceuticals are significantly influenced by healthcare policy and regulatory bodies in Brazil. The National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, or ANVISA) is the regulatory body in Brazil in charge of drug approval and oversight. Pharmaceutical products, including treatment medications, must be evaluated and approved by ANVISA, a regulatory body under the Brazilian Ministry of Health. Before pharmaceuticals are made available to the general public, the FDA makes sure medicines meet safety, effectiveness, and quality requirements. To track a drug's efficacy and safety after it is put on the market, ANVISA also conducts post-marketing surveillance. The Ministry of Health in Brazil is responsible for creating healthcare policies that cover a range of issues, including drug prices, reimbursement guidelines, and healthcare service accessibility. The Unified Health System, also known as Sistema Único de Saúde (SUS), is Brazil's public healthcare system that strives to give all inhabitants access to healthcare services.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Abbott
• Johnson & Johnson
• Teva Pharmaceutical
• Roche
• Merck & Co.